Who are ABACAVIR SULFATE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tivicay, Hepsera, Epivir, Retrovir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abacavir-sulfate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ABACAVIR SULFATE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABACAVIR SULFATE (ABACAVIR SULFATE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC].

marketed Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

ABACAVIR SULFATE (ABACAVIR SULFATE).

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABACAVIR SULFATE TARGET	ABACAVIR SULFATE		marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		1998-01-01
Tivicay	DOLUTEGRAVIR	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Transmembrane protein 97	2013-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Epivir	LAMIVUDINE	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Deoxycytidine kinase	1995-01-01
Retrovir	ZIDOVUDINE	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Thymidine kinase, cytosolic	1987-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class)

GSK · 3 drugs in this class
· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABACAVIR SULFATE — Competitive Intelligence Brief. https://druglandscape.com/ci/abacavir-sulfate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing